Cargando…
Harm Minimisation Drug Policy Implementation Qualities: Their Efficacy with Australian Needle and Syringe Program Providers and People Who Inject Drugs
(1) Background: Policies and laws in several jurisdictions across the globe have aimed to promote harm minimisation or reduction, through the implementation of Needle and Syringe Programs (NSP) for people who inject drugs (PWID), for whom abstinence may not be possible or desired. While NSPs hold gr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141102/ https://www.ncbi.nlm.nih.gov/pubmed/35627918 http://dx.doi.org/10.3390/healthcare10050781 |
_version_ | 1784715261932208128 |
---|---|
author | Resiak, Danielle Mpofu, Elias Rothwell, Roderick |
author_facet | Resiak, Danielle Mpofu, Elias Rothwell, Roderick |
author_sort | Resiak, Danielle |
collection | PubMed |
description | (1) Background: Policies and laws in several jurisdictions across the globe have aimed to promote harm minimisation or reduction, through the implementation of Needle and Syringe Programs (NSP) for people who inject drugs (PWID), for whom abstinence may not be possible or desired. While NSPs hold great promise, their implementation qualities are understudied. (2) Aim: We aimed to examine the implementation quality priorities of NSP providers and PWID consumers in an Australian setting. (3) Method: This study utilised a Quantitative-qualitative (QUAN-qual) mixed methods approach. Survey participants included both PWID (n = 70) and NSP providers (n = 26) in Australia. (4) Results: Results following non-parametric data analysis indicate NSP providers prioritised NSP implementation qualities in the following order: compatibility, observability, relative advantage, resourcing and trialability. Contrary to which, PWID prioritised resourcing, compatibility, relative advantage and trialability, respectively. Findings demonstrate that efficacy of implementation qualities is dependent on the juxtaposition of service provision and utilisation whereby implementation quality priorities are balanced. (5) Conclusions: This research presents novel findings guiding NSP harm reduction programmes for sustainability framed on provider and consumer implementation quality priorities. We envisage future studies on boundary conditions of NSP harm reduction implementation in other jurisdictions. |
format | Online Article Text |
id | pubmed-9141102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91411022022-05-28 Harm Minimisation Drug Policy Implementation Qualities: Their Efficacy with Australian Needle and Syringe Program Providers and People Who Inject Drugs Resiak, Danielle Mpofu, Elias Rothwell, Roderick Healthcare (Basel) Article (1) Background: Policies and laws in several jurisdictions across the globe have aimed to promote harm minimisation or reduction, through the implementation of Needle and Syringe Programs (NSP) for people who inject drugs (PWID), for whom abstinence may not be possible or desired. While NSPs hold great promise, their implementation qualities are understudied. (2) Aim: We aimed to examine the implementation quality priorities of NSP providers and PWID consumers in an Australian setting. (3) Method: This study utilised a Quantitative-qualitative (QUAN-qual) mixed methods approach. Survey participants included both PWID (n = 70) and NSP providers (n = 26) in Australia. (4) Results: Results following non-parametric data analysis indicate NSP providers prioritised NSP implementation qualities in the following order: compatibility, observability, relative advantage, resourcing and trialability. Contrary to which, PWID prioritised resourcing, compatibility, relative advantage and trialability, respectively. Findings demonstrate that efficacy of implementation qualities is dependent on the juxtaposition of service provision and utilisation whereby implementation quality priorities are balanced. (5) Conclusions: This research presents novel findings guiding NSP harm reduction programmes for sustainability framed on provider and consumer implementation quality priorities. We envisage future studies on boundary conditions of NSP harm reduction implementation in other jurisdictions. MDPI 2022-04-22 /pmc/articles/PMC9141102/ /pubmed/35627918 http://dx.doi.org/10.3390/healthcare10050781 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Resiak, Danielle Mpofu, Elias Rothwell, Roderick Harm Minimisation Drug Policy Implementation Qualities: Their Efficacy with Australian Needle and Syringe Program Providers and People Who Inject Drugs |
title | Harm Minimisation Drug Policy Implementation Qualities: Their Efficacy with Australian Needle and Syringe Program Providers and People Who Inject Drugs |
title_full | Harm Minimisation Drug Policy Implementation Qualities: Their Efficacy with Australian Needle and Syringe Program Providers and People Who Inject Drugs |
title_fullStr | Harm Minimisation Drug Policy Implementation Qualities: Their Efficacy with Australian Needle and Syringe Program Providers and People Who Inject Drugs |
title_full_unstemmed | Harm Minimisation Drug Policy Implementation Qualities: Their Efficacy with Australian Needle and Syringe Program Providers and People Who Inject Drugs |
title_short | Harm Minimisation Drug Policy Implementation Qualities: Their Efficacy with Australian Needle and Syringe Program Providers and People Who Inject Drugs |
title_sort | harm minimisation drug policy implementation qualities: their efficacy with australian needle and syringe program providers and people who inject drugs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141102/ https://www.ncbi.nlm.nih.gov/pubmed/35627918 http://dx.doi.org/10.3390/healthcare10050781 |
work_keys_str_mv | AT resiakdanielle harmminimisationdrugpolicyimplementationqualitiestheirefficacywithaustralianneedleandsyringeprogramprovidersandpeoplewhoinjectdrugs AT mpofuelias harmminimisationdrugpolicyimplementationqualitiestheirefficacywithaustralianneedleandsyringeprogramprovidersandpeoplewhoinjectdrugs AT rothwellroderick harmminimisationdrugpolicyimplementationqualitiestheirefficacywithaustralianneedleandsyringeprogramprovidersandpeoplewhoinjectdrugs |